Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 55% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
The latest announcement is out from GlaxoSmithKline ( (GB:GSK) ).
GSK plc has announced its total voting rights and capital as of September 30, 2025. The company’s issued share capital consists of over 4.3 billion ordinary shares, with a total of approximately 4.07 billion voting rights available. This information is crucial for shareholders to determine their required notifications under the Financial Conduct Authority’s rules.
The most recent analyst rating on (GB:GSK) stock is a Hold with a £14.50 price target. To see the full list of analyst forecasts on GlaxoSmithKline stock, see the GB:GSK Stock Forecast page.
Spark’s Take on GB:GSK Stock
According to Spark, TipRanks’ AI Analyst, GB:GSK is a Outperform.
GlaxoSmithKline’s strong financial performance and positive earnings call are the most significant factors driving the score. The company’s strategic focus on specialty medicines and shareholder returns, combined with a reasonable valuation and positive technical indicators, support a favorable outlook. Challenges in vaccine sales and regulatory headwinds are noted but are balanced by the company’s innovation and growth initiatives.
To see Spark’s full report on GB:GSK stock, click here.
More about GlaxoSmithKline
GlaxoSmithKline (GSK) is a leading pharmaceutical company that operates in the healthcare industry. It specializes in the development and production of vaccines, medicines, and consumer healthcare products, focusing on improving global health outcomes.
Average Trading Volume: 7,773,304
Technical Sentiment Signal: Strong Buy
Current Market Cap: £61.1B
Learn more about GSK stock on TipRanks’ Stock Analysis page.